Literature DB >> 23463742

Use of number needed to treat in cost-effectiveness analyses.

Vishvas Garg1, Xian Shen, Yan Cheng, James J Nawarskas, Dennis W Raisch.   

Abstract

OBJECTIVE: To review the use of number needed to treat (NNT) and/or number needed to harm (NNH) values to determine their relevance in helping clinicians evaluate cost-effectiveness analyses (CEAs). DATA SOURCES: PubMed and EconLit were searched from 1966 to September 2012. STUDY SELECTION AND DATA EXTRACTION: Reviews, editorials, non-English-language articles, and articles that did not report NNT/NNH or cost-effectiveness ratios were excluded. CEA studies reporting cost per life-year gained, per quality-adjusted life-year (QALY), or other cost per effectiveness measure were included. Full texts of all included articles were reviewed for study information, including type of journal, impact factor of the journal, focus of study, data source, publication year, how NNT/NNH values were reported, and outcome measures. DATA SYNTHESIS: A total of 188 studies were initially identified, with 69 meeting our inclusion criteria. Most were published in clinician-practice-focused journals (78.3%) while 5.8% were in policy-focused journals, and 15.9% in health-economics-focused journals. The majority (72.4%) of the articles were published in high-impact journals (impact factor >3.0). Many articles focused on either disease treatment (40.5%) or disease prevention (40.5%). Forty-eight percent reported NNT as a part of the CEA ratio per event. Most (53.6%) articles used data from literature reviews, while 24.6% used data from randomized clinical trials, and 20.3% used data from observational studies. In addition, 10% of the studies implemented modeling to perform CEA.
CONCLUSIONS: CEA studies sometimes include NNT ratios. Although it has several limitations, clinicians often use NNT for decision-making, so including NNT information alongside CEA findings may help clinicians better understand and apply CEA results. Further research is needed to assess how NNT/NNH might meaningfully be incorporated into CEA publications.

Entities:  

Mesh:

Year:  2013        PMID: 23463742     DOI: 10.1345/aph.1R417

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  12 in total

1.  [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].

Authors:  D Anderson; J Lehmann; T Ecker; S Vosgerau; V Donatz
Journal:  Urologe A       Date:  2017-07       Impact factor: 0.639

Review 2.  Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.

Authors:  William S Bush; Jessica N Cooke Bailey; Mark F Beno; Dana C Crawford
Journal:  Public Health Genomics       Date:  2019-08-27       Impact factor: 2.000

3.  Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort.

Authors:  Paula Byrne; John Cullinan; Paddy Gillespie; Rafael Perera; Susan M Smith
Journal:  Br J Gen Pract       Date:  2019-04-23       Impact factor: 5.386

4.  Number Needed to Quarantine and Proportion of Prevented Infectious Days by Quarantine: Evaluating the Effectiveness of COVID-19 Contact Tracing.

Authors:  Diogo Fernandes da Silva; João Vasco Santos; Filipa Santos Martins
Journal:  Public Health Rep       Date:  2022-08-20       Impact factor: 3.117

5.  Group Prenatal Care Results in Medicaid Savings with Better Outcomes: A Propensity Score Analysis of CenteringPregnancy Participation in South Carolina.

Authors:  Sarah Gareau; Ana Lòpez-De Fede; Brandon L Loudermilk; Tammy H Cummings; James W Hardin; Amy H Picklesimer; Elizabeth Crouch; Sarah Covington-Kolb
Journal:  Matern Child Health J       Date:  2016-07

6.  Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.

Authors:  Tsung-Ying Lee; Shihchen Kuo; Chen-Yi Yang; Huang-Tz Ou
Journal:  Br J Clin Pharmacol       Date:  2020-01-23       Impact factor: 4.335

7.  Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms.

Authors:  Joost G E Verbeek; Vera Atema; Janne C Mewes; Marieke van Leeuwen; Hester S A Oldenburg; Marc van Beurden; Myra S Hunter; Wim H van Harten; Neil K Aaronson; Valesca P Retèl
Journal:  Breast Cancer Res Treat       Date:  2019-08-26       Impact factor: 4.872

8.  Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.

Authors:  Chen-Yi Yang; Ying-Ren Chen; Huang-Tz Ou; Shihchen Kuo
Journal:  Cardiovasc Diabetol       Date:  2021-01-19       Impact factor: 9.951

9.  Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost.

Authors:  Charles M Zelen; Thomas E Serena; Lisa Gould; Lam Le; Marissa J Carter; Jennifer Keller; William W Li
Journal:  Int Wound J       Date:  2015-12-23       Impact factor: 3.315

Review 10.  Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept.

Authors:  Lakshminarayanan Varadhan; Ponnusamy Saravanan; Sarah N Ali; Wasim Hanif; Vinod Patel
Journal:  Clin Drug Investig       Date:  2022-02-02       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.